STANDARD BIOTOOLS INC. 8K

Standard BioTools Inc. filed a non-binding Share and Asset Purchase Agreement as an exhibit outlining the contemplated sale of its mass cytometry-based business to Multiplex Bio Inc., subject to definitive execution, stockholder approval, and other conditions.

The Form 8-K includes as Exhibit 2.1 a Share and Asset Purchase Agreement, dated as of July 28, 2026, between Standard BioTools Inc. (as seller) and Multiplex Bio Inc. (as buyer), which sets forth the proposed terms under which Standard BioTools would sell to Multiplex Bio both equity interests in certain "Transferred Companies" and specified assets and liabilities comprising Standard BioTools’ mass cytometry-based business (including its CyTOF and Hyperion spatial biology platforms, Maxpar reagents, and the Theia next-generation XTi platform), while excluding its separate microfluidics business; the agreement details the structure of the contemplated sale, purchase price mechanics (including a base seller note and working capital adjustments), conditions to closing, termination rights and fees, covenants such as non-compete and employee matters, and the need for Standard BioTools stockholder approval, but also states that the document is to facilitate discussion of a possible transaction and is not itself a binding agreement unless and until executed and delivered by the parties.

Filing Facts

CIK

1162194

Ticker

-

Form

8K

Source Type

sec

Accession

0001140361-26-029964

Alert Tier

8